Adma Biologics Stock Price, News & Analysis

ADMA Biologics, Inc. (Nasdaq: ADMA) is hosting an exclusive educational event at IDWeek 2020 on respiratory viral infections, featuring experts Dr. Michael Ison and Dr. Lisa Forbes Satter. The session on October 22 will focus on managing infections in immunocompromised patients. Additionally, new data on Streptococcus pneumoniae will be presented in an on-demand session. ADMA Biologics develops specialty plasma-derived biologics for immunodeficient patients, with FDA-approved products including ASCENIV™, BIVIGAM®, and NABI-HB® to combat infectious diseases.

ADMA Biologics, a biopharmaceutical company, will have its CEO Adam Grossman participate in a fireside chat at the Morgan Stanley Virtual Healthcare Conference on September 14, 2020, at 4:30 p.m. ET. This event will provide insights into the company's operations and product offerings, focusing on specialty plasma-derived biologics for immunodeficient patients. A webcast of the event will be available on the ADMA website and archived for 90 days. ADMA manufactures three FDA-approved products for treating immune deficiencies and infectious diseases.

ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CEO Adam Grossman will participate in several investor conferences in September 2020. The events include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 2:30 p.m. ET, Cantor Virtual Global Healthcare Conference on September 17 at 11:20 a.m. ET, and Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on September 22 at 9:10 a.m. ET. Webcasts will be available on ADMA's website and archived for 90 days.

ADMA Biologics reported $18 million in total revenues for the first half of 2020, reflecting a 78% increase year-over-year. Despite a 19% revenue growth in Q2 compared to 2019, the company faced disruptions due to COVID-19, affecting product testing and supply chains. ADMA opened a new plasma center and joined the CoVIg-19 Plasma Alliance. It anticipates generating $250 million in annual revenue within three to five years. However, net loss for Q2 reached $20.2 million, up from $13.2 million in Q2 2019, driven by increased operational costs.

ADMA Biologics, Inc. (ADMA) announced a live conference call scheduled for August 5, 2020, at 4:30 p.m. ET to discuss its business highlights and financial results for Q2 2020, ending June 30, 2020. The call can be accessed via phone or through an audio webcast available on ADMA's investor relations website. The company is focused on manufacturing and developing plasma-derived biologics targeting immunodeficient patients.

ADMA Biologics announced the opening of its second plasma collection facility, ADMA BioCenters, in Knoxville, TN. This facility is part of ADMA's plan to establish 5 to 10 new centers by the end of 2022. A Biologics License Application (BLA) has been submitted to the FDA for approval, expected by mid-2021. The Knoxville center features modern equipment and amenities to enhance donor experience. Until FDA approval, ADMA can collect plasma, which will then be used for production of its FDA-approved immunoglobulin products.

ADMA Biologics announced the approval of Martha J. Demski's election to its Board of Directors during the Annual Shareholder Meeting on June 18, 2020. Ms. Demski brings over 35 years of biotechnology experience, previously serving as CFO at Ajinomoto Althea and holding positions at Vical and the Sidney Kimmel Cancer Center. Her financial expertise is expected to bolster ADMA's growth, especially with products like BIVIGAM and ASCENIV. ADMA is focused on expanding its plasma collection facilities and developing novel immunoglobulin products for immunodeficient patients.

ADMA Biologics (ADMA) announced key corporate achievements aimed at improving its supply chain and production capacity. The company successfully manufactured three BIVIGAM® conformance batches at a larger plasma volume, anticipates quicker market turnaround, and has installed a new aseptic filling machine to enhance production capabilities. These initiatives are expected to streamline operations and reduce costs, aligning with ADMA's objectives for 2020. Additionally, construction is underway for new plasma collection centers in Tennessee, further supporting their production needs.